Studies luspatercept in adults with transfusion-dependent beta-thalassemia
Looks at luspatercept use in adults with beta-thalassemia who need regular blood transfusions.
Plain-language title generated from the registry record
Registry title: A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
Key facts
- Where
- Seeb, OmanSee the site
Where in Oman
- Sultan Qaboos University HospitalSeeb, OmanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07215975
- Record updated
- 19 August 2026
- Original description
The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle EastRead full original descriptionShow less
REal-World Application of Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (RELATE): A Non-interventional Retrospective and Prospective Observational Study
The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East
Inclusion: Male or female participants of any race aged at least 18 years at time of initiation of luspatercept treatment; Participants with documented diagnosis of transfusion-dependent β-thalassemia (TDT); Participants who have been initiated on treatment with luspatercept as per the product's Summary of Product Characteristics (SmPC) no longer than 12 months prior to informed consent signature, and for whom therapy is ongoing; Participants for whom the decision to prescribe luspatercept treatment is clearly separated from the physician's decision to include the participant in the current study; Participants who have provided signed informed consent for participating in the study and for collecting and analyzing medical data pertinent to the objectives of this study.
Exclusion: Participants who are currently receiving or are planned to receive treatment with any investigational drug/device/intervention or who have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to luspatercept therapy initiation; Participants that meet any of the contraindications to the administration of luspatercept as outlined in the latest version of the locally approved SmPC; Participants who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period; Participants who have not provided signed informed consent for participating in the study and for collecting and analysing medical data pertinent to the objectives of this study.